Alexander Shadbolt

Arctoris is a tech-enabled Partnership Research Organization (PRO) headquartered in Oxford. We combine our unique automation platform, Ulysses, with a world-class team of excellent laboratory scientists to guide and rapidly progress our partners’ drug discovery programs from target to candidate. Data is the lifeblood of research, and “Better Data leads to Better Decisions”. Our excellent service is built on: 1) Data quality: generating large reproducible datasets by leveraging robotics and wet lab automation, in turn empowering improved decision-making. 2) Our world-class team of experienced scientists: a true partner for your discovery work, consulting and advising on assay cascades and the path from target all the way to the clinic. 3) An "ecosystem of excellence”: we are a full-suite discovery PRO with partners in all adjacent disciplines, which allows us to stay agile and truly client-focused.

Akrivia Health was founded to answer a critical question: Why is mental health and dementias research still decades behind? Spun out of the NHS and Oxford University in 2019, we’re focused on curating the world’s most in-depth neuropsychiatric and neurodegenerative dataset – linking structured and unstructured EHRs with genomic and longitudinal insights. Because what is urgently needed in this space is faster access to better quality data. Our AI-enabled solutions apply advanced NLP to extract deep phenotypic signals from clinical notes, enabling patient stratification, outcome tracking, and real-world evidence generation. Through this, we enable researchers, pharma, and healthcare providers to evaluate treatment effectiveness, optimise clinical trials, and drive precision care. Join us to transform the future of mental health and dementias and improve lives – one data point at a time.

Formed in late 2017, AMLo Biosciences is dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify patients’ true risk of disease progression. Those patients who are genuinely at low-risk of disease spread can be provided reassurance and better-informed follow-up care, while those identified at risk of metastasis are enabled to receive timely treatment. The test under development – AMBLor® – will be simple to use and fits seamlessly into current diagnostic practice. AMLo Biosciences has been founded by a team with an internationally acclaimed research track record in the melanoma field, through identification of translational biomarkers, drug discovery & development and the building of biotech companies.

Nutri-San is a seaweed technology business first established in Vietnam in 2017. We produce supplements made from a blend of natural seaweeds for the animal feed industry. Our supplements improve animal health and food productivity and eliminate the need for the synthetic and pharmaceutically-derived additives commonly used in animal feeds. We are a company and a movement dedicated to protecting our environment and improving animal and human health. Success for us means that people, animals and our planet flourish now and in the future. Seaweed has been used for thousands of years to deliver health benefits for humans and animals. Today these benefits are backed by science, yet seaweed remains one of the worlds most underutilized resources. Nutri-San aims to change this by scaling a seaweed technology business that impacts some of the most pressing challenges we face globally - from combating climate change and feeding humans and animals better, to driving innovations in biotechnology, agriculture & medicine, and supporting marginalized coastal communities. Our impact focus is closely aligned to the United Nations Sustainable Development Goals. We are currently actively working towards SDGs 1, 3, 8, 13 and 14.

Future Planet is the impact-led, global venture capital firm built to back growth companies emerging from the founders and science from the worlds top universities. Through a unique series of partnerships and relationships around leading universities, Future Planet has an unrivalled global level of access to entrepreneurs and businesses profitably solving the worlds greatest challenges in Climate Change, Education, Health, Sustainable Growth & Security. Our mission is not simply to deliver excellent returns but to create a lasting impact: by connecting the worlds largest investors with its best minds, we believe we can profitably address the greatest challenges that humanity faces today. The Future Planet Fund has been designed in close conjunction with sophisticated investors in order to provide multi-stage access to start-ups, spin-outs and growing companies, at a scale large enough to suit major sovereign wealth funds and similar institutions.

UK Private Capital (formerly the British Private Equity and Venture Capital Association - BVCA) is the association of the UK private capital industry. We represent 600 firms including the wider ecosystem of professional advisers and investors.   Private capital consists of private equity and venture capital which make long-term investments to grow British businesses and build a better economy. Private credit and venture debt provide active and engaged debt finance to businesses.  The private capital industry backs 13,000 UK businesses, nine in 10 of which are small or medium-sized enterprises. Businesses backed by the industry employ 2.5 million people across the UK and contribute 7% to GDP.  In 2024, £29.4bn was invested by private capital into UK businesses in sectors across the UK economy, ranging from consumer products to emerging technology. This increased investment has fuelled the growth of businesses across the UK, with six in ten (58%) of the businesses backed in 2024, located outside of the capital.  These investments are long term, with an average investment period of six years, in contrast to less than a year in public markets.  UK-based private capital specialists have raised £190bn of funds, known as dry powder, which is expected to be invested over the next three to five years.   The industry invests for a better future by backing some of the UK’s best loved businesses, developing the companies of the future and delivering solutions to global problems. 

Arctoris is a tech-enabled Partnership Research Organization (PRO) headquartered in Oxford. We combine our unique automation platform, Ulysses, with a world-class team of excellent laboratory scientists to guide and rapidly progress our partners’ drug discovery programs from target to candidate. Data is the lifeblood of research, and “Better Data leads to Better Decisions”. Our excellent service is built on: 1) Data quality: generating large reproducible datasets by leveraging robotics and wet lab automation, in turn empowering improved decision-making. 2) Our world-class team of experienced scientists: a true partner for your discovery work, consulting and advising on assay cascades and the path from target all the way to the clinic. 3) An "ecosystem of excellence”: we are a full-suite discovery PRO with partners in all adjacent disciplines, which allows us to stay agile and truly client-focused.

Akrivia Health was founded to answer a critical question: Why is mental health and dementias research still decades behind? Spun out of the NHS and Oxford University in 2019, we’re focused on curating the world’s most in-depth neuropsychiatric and neurodegenerative dataset – linking structured and unstructured EHRs with genomic and longitudinal insights. Because what is urgently needed in this space is faster access to better quality data. Our AI-enabled solutions apply advanced NLP to extract deep phenotypic signals from clinical notes, enabling patient stratification, outcome tracking, and real-world evidence generation. Through this, we enable researchers, pharma, and healthcare providers to evaluate treatment effectiveness, optimise clinical trials, and drive precision care. Join us to transform the future of mental health and dementias and improve lives – one data point at a time.

Formed in late 2017, AMLo Biosciences is dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify patients’ true risk of disease progression. Those patients who are genuinely at low-risk of disease spread can be provided reassurance and better-informed follow-up care, while those identified at risk of metastasis are enabled to receive timely treatment. The test under development – AMBLor® – will be simple to use and fits seamlessly into current diagnostic practice. AMLo Biosciences has been founded by a team with an internationally acclaimed research track record in the melanoma field, through identification of translational biomarkers, drug discovery & development and the building of biotech companies.

Nutri-San is a seaweed technology business first established in Vietnam in 2017. We produce supplements made from a blend of natural seaweeds for the animal feed industry. Our supplements improve animal health and food productivity and eliminate the need for the synthetic and pharmaceutically-derived additives commonly used in animal feeds. We are a company and a movement dedicated to protecting our environment and improving animal and human health. Success for us means that people, animals and our planet flourish now and in the future. Seaweed has been used for thousands of years to deliver health benefits for humans and animals. Today these benefits are backed by science, yet seaweed remains one of the worlds most underutilized resources. Nutri-San aims to change this by scaling a seaweed technology business that impacts some of the most pressing challenges we face globally - from combating climate change and feeding humans and animals better, to driving innovations in biotechnology, agriculture & medicine, and supporting marginalized coastal communities. Our impact focus is closely aligned to the United Nations Sustainable Development Goals. We are currently actively working towards SDGs 1, 3, 8, 13 and 14.